Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol

November 2004

Researchers are excited about Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol.

The lay press has picked up on this too-good-to-be-true drug, and people are asking about it.

It's the first in a new class...called selective cannabinoid type 1 (CB1) blockers.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Lots of patients are asking about alternatives to Vioxx
Osteoporosis Do carbonated beverages cause bone loss
Women s Health Diflucan once a WEEK to PREVENT recurrent vaginal yeast infections
Women s Health new MONTHLY option for contraception
Renal Urology Oxytrol, the first PATCH for treating overactive bladder
Anticoagulants stop warfarin prior to surgery or other invasive procedures
Anticoagulants Exanta (ximelagatran) won't be approved and won't be replacing warfarin any time soon
Neurology Pain Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol
Pediatrics Croup will be treated more frequently with dexamethasone
Pediatrics Nuvo lotion for head lice
Gastroenterology Celiac patients need to avoid gluten in foods and drugs
Migraine new triptan called Relpax
Cardiology risk of potentially fatal arrhythmias with erythromycin
Infectious Diseases New treatments are being used for skin infections